BioSpace News Archive

Novo to Discontinue Long-Acting Insulin Injection Levemir by the End of 2024

Citing manufacturing concerns and formulary losses, Novo Nordisk will discontinue its long-acting insulin Levemir by the end of next year amid strong pressure from U.S. lawmakers to lower insulin prices.

November 9, 2023
·
2 min read
·
Tristan Manalac
Business

AstraZeneca Targets Obesity Market with Potential $2B Deal for Early GLP-1 Candidate

In a bid to join Eli Lilly and Novo Nordisk in the lucrative, high-growth obesity market, AstraZeneca is investing in a Phase I oral GLP-1RA candidate from Shanghai-based biotech Eccogene.

November 9, 2023
·
2 min read
·
Tristan Manalac
Business

Novavax Q3 Revenue Slumps on Low Vaccination Rates, Trims 2023 Outlook

The vaccine maker is prepared to cut another $300 million in operating expenses in 2024 to keep the company afloat as it works to get its combination COVID-19/flu vaccine into Phase III.

November 9, 2023
·
2 min read
·
Kate Goodwin
Business

Biogen Gets Q3 Beat, Reduces Full-Year Guidance on Costs of Reata Buy

While the biotech’s third-quarter revenue beat Wall Street expectations, its $7.3 billion acquisition of Reata Pharmaceuticals—which closed in September—negatively impacted 2023 per-share earnings.

November 9, 2023
·
2 min read
·
Tyler Patchen
Policy

FTC Challenges Over 100 Patents Listed on FDA’s Orange Book

The Federal Trade Commission is challenging over 100 pharmaceutical patents held by prominent drugmakers, including AbbVie, AstraZeneca and Boehringer Ingelheim, for their listings.

November 9, 2023
·
2 min read
·
Tyler Patchen
FDA

Takeda Wins FDA Approval for Fruquintinib in Certain Colorectal Cancer Patients

The oral targeted therapy, now sold under the brand name Fruzaqla, is approved for adults with metastatic colorectal cancer who have received certain previous treatments for the disease.

November 9, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Cell & Gene Therapy Space Gears Up for First CRISPR Approval

As Vertex and CRISPR Therapeutics await the monumental potential approval of exa-cel, bluebird bio, Iovance and Rocket Pharmaceuticals wait patiently in the wings.

November 9, 2023
·
6 min read
·
Jill Neimark
Policy

FDA Action Alert: Pacira, CorMedix, Aldeyra and More

Over the next two weeks, the FDA is set to decide on New Drug Applications from Pacira, CorMedix and Aldeyra and hold an advisory committee meeting for two overdue confirmatory trials from Acrotech.

November 9, 2023
·
5 min read
·
Tristan Manalac
Angle PLC Announces Launch of PD-L1 Test to Support Cancer Studies

ANGLE plc is delighted to announce the launch of its Portrait® PD-L1 test for the evaluation of PD-L1 protein expression on CTCs following extensive development and optimisation.

November 9, 2023
·
5 min read
Business

AlzeCure Publishes its Interim Report for January - September 2023

AlzeCure Pharma AB announced that its interim report for the period January - September 2023 is now available on the company’s website.

November 9, 2023
·
5 min read